1-3 of 3
Kate Burbury
Close
Sort by
Journal Articles

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study

Clinical Trials & Observations
John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron Gerds, Vikas Gupta, Brian Higgins, Kathrin Wonde, Candice Jamois, Bruno Kovic, Ling-Yuh Huw, Sudhakar Katakam, Margherita Maffioli, Ruben Mesa, Jeanne Palmer, Marta Bellini, David M. Ross, Alessandro M. Vannucchi, Abdulraheem Yacoub
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1162–1174.
https://doi.org/10.1182/bloodadvances.2021006043
Published: 2022
Includes: Supplemental data
Journal Articles

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia

Clinical Trials & Observations
Adrian G. Minson, Katherine Cummins, Lucy Fox, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Shaun Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf, Faye Putt, Andrew Grigg
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1084–1091.
https://doi.org/10.1182/bloodadvances.2018028035
Published: 2019
Includes: Supplemental data
Journal Articles

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Clinical Trials & Observations
Lucy C. Fox, Katherine D. Cummins, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Shaun Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf, Faye Putt, Andrew Grigg
Journal: Blood Advances
Blood Adv (2017) 1 (13): 802–811.
https://doi.org/10.1182/bloodadvances.2016003889
Published: 2017